The Hydrus Microstent dilates and scaffolds Schlemm’s canal. More than 2,000 people in 21 countries have been treated with the Hydrus, and recruitment for the company’s U.S. pivotal trial is now complete (n=558).
When in place, the device creates a cross-sectional stent that increases the cross-sectional diameter of Schlemm’s canal by “about 4-5 times,” Van Meter said.
In European studies, the average pressure was 19 mmHg with two medications (n=100). Of those in the Hydrus-phaco group, 73% remained medication-free for more than 2 years, compared to only 38% of the phaco patients. Once the medications were washed out, there is decreased efficacy in managing pressures with phaco that is not seen with the Hydrus at 24 months (44% vs. 80%).
“With about 50% of the data collected in our 3 year analysis, we’re seeing even further separation between the two procedures,” he said.
David Van Meter
Dave joined Ivantis as President/CEO in 2008. Previously, starting in 2001, Dave worked at Abbott’s Vascular Division, where he was an early leader in the creation and growth of a business that grew from $60 to $400 MM from 2001 until 2006.